Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04204408 · ClinicalTrials.gov registry record · Phase 2
A Research Study Investigating Mim8 in People With Haemophilia A
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT04204408 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 275 participants.
The verdict
NCT04204408, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector. The study will last for up to 44 months. It consists of a main phase (part 1 and part 2) and an extension phase. In part 1, participants will be injected only once with either Mim8 or a "dummy" medicine (placebo) - which one will be decided by chance. In part 2 and the extension phase participants will get an Mim8 injection weekly or monthly.
Interventions
- DRUG NNC0365-3769 (Mim8)
- DRUG Placebo (Mim8)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04204408
The ClinicalTrials.gov registry entry for NCT04204408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC0365-3769 (Mim8) is the first listed.
NCT04204408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04204408 about?
NCT04204408 is a clinical study titled "A Research Study Investigating Mim8 in People With Haemophilia A". This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will b...
What is the current status of trial NCT04204408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2020-01-10. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT04204408?
The interventions under investigation include: NNC0365-3769 (Mim8) (DRUG), Placebo (Mim8) (DRUG).
Who is sponsoring clinical trial NCT04204408?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.